Literature DB >> 8630287

Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer.

M Díez1, A Torres, M L Maestro, M D Ortega, A Gómez, M Pollán, J A Lopez, A Picardo, F Hernando, J L Balibrea.   

Abstract

Risk of death and risk of recurrence in 108 potentially curable non-small-cell lung cancer patients were analysed with respect of TNM stage, histological type and carcinoembryonic antigen (CEA), CA125 antigen and squamous cell carcinoma antigen (SCC) levels in serum and cytosol. CA125 and CEA levels were closely related to outcome figures. Multivariate analyses indicated that TNM stage and histological type had the best predictive power, but serum and cytosolic CA125 and serum CEA contained additional, independent prognostic information. Predictive information drawn from serum and cytosolic levels proved mutually complementary. We conclude that CA125 and CEA complement TNM classification and histological type for the purpose of quantifying risk of death or recurrence.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8630287      PMCID： PMC2074500          DOI： 10.1038/bjc.1996.239

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  18 in total

1.  Prognostic factors in lung cancer.

Authors:  J S Lee; W K Hong
Journal:  N Engl J Med       Date:  1992-07-02       Impact factor: 91.245

Review 2.  Lung cancer biology.

Authors:  D N Carney
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

Review 3.  Surgical treatment of lung cancer.

Authors:  M S Bains
Journal:  Chest       Date:  1991-09       Impact factor: 9.410

Review 4.  A new international staging system for lung cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1986-04       Impact factor: 9.410

5.  Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy.

Authors:  T Shinkai; N Saijo; K Tominaga; K Eguchi; E Shimizu; Y Sasaki; J Fujita; H Futami; H Ohkura; K Suemasu
Journal:  Cancer       Date:  1986-04-01       Impact factor: 6.860

6.  Decline of posttreatment tumor marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictor.

Authors:  C H Spiridonidis; L R Laufman; K A Stydnicki; J W Noltimier; C C Cho; D C Young; W J Hicks; M L Segal; J T Guy; B L Zidar
Journal:  Cancer       Date:  1995-04-01       Impact factor: 6.860

Review 7.  The future of prognostic factors in outcome prediction for patients with cancer.

Authors:  L P Fielding; C M Fenoglio-Preiser; L S Freedman
Journal:  Cancer       Date:  1992-11-01       Impact factor: 6.860

Review 8.  Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung.

Authors:  G M Strauss; D J Kwiatkowski; D H Harpole; T J Lynch; A T Skarin; D J Sugarbaker
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

9.  Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group.

Authors:  M H Gail; R T Eagan; R Feld; R Ginsberg; B Goodell; L Hill; E C Holmes; J M Lukeman; C F Mountain; R K Oldham
Journal:  Cancer       Date:  1984-11-01       Impact factor: 6.860

10.  Serum CEA, CA125, and SCC antigens and tumor recurrence in resectable non-small cell lung cancer.

Authors:  M Diez; A Gomez; F Hernando; M D Ortega; M L Maestro; A Torres; J M Mugüerza; A Gutierrez; J Granell; J L Balibrea
Journal:  Int J Biol Markers       Date:  1995 Jan-Mar       Impact factor: 3.248
View more
  13 in total

1.  Evaluation of the clinical application of multiple tumor marker protein chip in the diagnostic of lung cancer.

Authors:  Xiaochuan Wang; Yi Zhang; Liangqi Sun; Shuaiping Wang; Jing Nie; Wenqing Zhao; Guobao Zheng
Journal:  J Clin Lab Anal       Date:  2018-05-07       Impact factor: 2.352

2.  Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer.

Authors:  Ryo Maeda; Takashi Suda; Ayumi Hachimaru; Daisuke Tochii; Sachiko Tochii; Yasushi Takagi
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

3.  Lung tumour markers in oncology practice: a study of TPA and CA125.

Authors:  G Buccheri; D Ferrigno
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

4.  Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer.

Authors:  D Korbakis; A Dimitromanolakis; I Prassas; G J Davis; E Barber; K L Reckamp; I Blasutig; E P Diamandis
Journal:  Br J Cancer       Date:  2015-07-16       Impact factor: 7.640

5.  Development and validation of a preoperative prognostic index independent of TNM stage in resected non-small cell lung cancer.

Authors:  Shogo Kumagai; Satoshi Marumo; Machiko Arita; Keiji Yamanashi; Ryota Sumitomo; Yosuke Otake; Tsuyoshi Shoji; Motonari Fukui; Toshiro Katayama; Norihito Okumura; Cheng-Long Huang
Journal:  BMC Pulm Med       Date:  2017-12-04       Impact factor: 3.317

6.  The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer.

Authors:  Linjie Liu; Jinlong Teng; Lijun Zhang; Peishan Cong; Yuan Yao; Guirong Sun; Zhijun Liu; Teng Yu; Mingjun Liu
Journal:  Biomed Res Int       Date:  2017-05-18       Impact factor: 3.411

7.  Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer.

Authors:  Jin Hur; Hye-Jeong Lee; Ji Eun Nam; Young Jin Kim; Yoo Jin Hong; Hee Yeong Kim; Se Kyu Kim; Joon Chang; Joo-Hang Kim; Kyung Young Chung; Hye Sun Lee; Byoung Wook Choi
Journal:  BMC Cancer       Date:  2012-09-07       Impact factor: 4.430

8.  Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.

Authors:  C Gu; T Oyama; T Osaki; J Li; M Takenoyama; H Izumi; K Sugio; K Kohno; K Yasumoto
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

9.  Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients.

Authors:  Dangfan Yu; Kaiqi Du; Taifeng Liu; Guojun Chen
Journal:  Int J Mol Sci       Date:  2013-05-27       Impact factor: 5.923

10.  The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types.

Authors:  Haiqing Chen; Fangqiu Fu; Yue Zhao; Haoxuan Wu; Hong Hu; Yihua Sun; Yawei Zhang; Jiaqing Xiang; Yang Zhang
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.